Is Johnson & Johnson a Buy After Its Latest Earnings Report?

Johnson & Johnson shares fell nearly 3% after Q2 results: total sales were ~$25.3B (up ~7% YoY) and adjusted net income rose ~6% to $7.08B ($2.90 EPS), slightly above consensus. Drug sales momentum was strong (Tremfya +73% to $2.0B; Darzalex +19% to $4.2B) but MedTech growth was held back by a 2% drop in Abiomed/Impella to $440M, linked to concerns raised by a U.K. study. J&J raised FY2026 guidance, lifting sales to ~$100.8B–$101.4B and adjusted EPS to ~$11.60–$11.75, but the market reaction suggests investors wanted more outsized outperformance versus peers.

Analysis

This looks like a valuation/multiple reaction more than a fundamental break. JNJ is being judged against a higher bar than a year ago: investors no longer pay up for “steady” in healthcare unless there is either faster top-line acceleration or a cleaner growth story than peers. The key implication is that the stock can still work operationally while underperforming the sector if capital rotates toward higher-growth pharma names; that creates a relative-value setup, not necessarily a broad thesis failure.

The more interesting read-through is the device unit. Abiomed’s softness matters less for one quarter of revenue than for what it says about physician confidence and procedure mix after the U.K. study. If that hesitation persists, the second-order hit is broader than JNJ: interventional cardiology suppliers and cath-lab adjacent names could see slower utilization, longer decision cycles, and weaker replacement demand over the next 1-3 quarters. This is a watch item for ABT and other medtech peers, but not yet enough evidence for an aggressive short.

The contrarian view is that the selloff may be too harsh because JNJ is still demonstrating portfolio replacement power: one franchise is rolling over while another is taking share inside the same therapeutic area. That kind of internal substitution typically supports earnings durability and dividend confidence over 6-18 months, even if it caps near-term multiple expansion. Falsifier: if next quarter shows Abiomed deterioration broadening beyond a study-driven wobble, or if MedTech growth remains sub-5% while pharma decelerates, the “quality compounder” case weakens.

Key Decisions for Investors

• Buy JNJ on further post-earnings weakness of 2-4% over the next 1-2 weeks; target a 3-6 month mean reversion trade, with upside tied to validation that raised guidance is sustainable. Falsify if the next print shows MedTech still slowing and FY EPS guidance is cut back.
• Do not chase the dip in ABT/MDT yet, but put both on alert for 1-3 month follow-through if interventional cardiology commentary weakens again; that would confirm a broader procedure-demand air pocket. No short until there is evidence of volume deterioration outside Abiomed.